Blood and Marrow Transplantation Reviews: Optimal Use of Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma

The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.

Blood and Marrow Transplantation Reviews: Examining Targeted Therapies for Hodgkin Lymphoma in the Post-Transplant Setting: Reason for Optimism

Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.

The Impact of Reduced-Intensity Conditioning Regimens in Transplant Outcomes

Pre-transplant conditioning can significantly influence post-transplant outcomes. A strong anti-tumor effect achieved by myeloablative conditioning (MAC) is frequently counterbalanced by higher morbidity and non-relapse mortality, particularly in older adults. On the other hand, reduced intensity conditioning (RIC) is associated with lower post-transplant mortality, but may not be sufficient enough to prevent relapse, particularly in patients with persistent and aggressive malignances.

Grand Rounds in Hematology: How the Experts Treat Hematologic Malignancies in 2012

According to the American Cancer Society, it was estimated in 2011 there were 44,600 cases of leukemia, 66,360 cases of non-Hodgkin lymphoma, 8,830 cases of Hodgkin lymphoma, and 20,520 cases of myeloma diagnosed for the first time. In addition, the Leukemia and Lymphoma Society estimates that one person is diagnosed with a blood cancer approximately every four minutes in the U.S. The outcome for patients with hematologic malignancies has dramatically changed with the use of novel therapies.